The Biden administration has abandoned a proposal to require drug companies to disclose prices and research costs of drugs affecting state Medicaid programs. This decision came after pressure from pharmaceutical companies and lobbying groups who threatened to sue if the government proceeded. This move showcases the administration’s reluctance to challenge the powerful drug industry, especially in light of a recent Supreme Court decision making it easier for the industry to challenge federal rules. The scrapped rule highlights the industry’s resistance to transparency and government oversight, particularly in relation to drug pricing and spending in healthcare programs.
Source link
Medicaid drug price survey proposal axed after pharma pressure
